AAIC 2017: Electronic Self-Administered Test Performs Similarly to Pen-and-Paper Version in Detecting MCI and Early Dementias

 

Findings presented at the Alzheimer’s Association International Conference in London indicate that the self-administered eSAGE (BrainTest Inc.) test performs similar to its validated pen-and-paper counterpart (SAGE) in detecting mild cognitive impairment and early dementias. Led by Douglas W. Scharre, MD, Professor of Clinical Neurology and Psychiatry at The Ohio State University Wexner Medical Center, investigators randomly selected individuals aged 50 and over who had taken SAGE to participate in a clinical evaluation including neuropsychological evaluations over an 18-month period. SAGE and eSAGE were administered using a crossover design. They found that eSAGE performs similarly with neuropsychological batteries, MoCA, and MMSE and shows no scale bias compared to the paper test. eSAGE had a high sensitivity (71 percent) and specificity (90 percent) in detecting cognitive impairment from normal participants. The results of the study were recently published in Alzheimer’s Research & Therapy.

To learn more about eSAGE, read Practical Neurology®’s Q&A with Dr. Scharre from the January/February 2017 edition

 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

 
  • BRYN MAWR COMMUNICATIONS III, LLC